Originally Published by Gilead Sciences
Racism and the impact of social determinants of health drive disparities in outcomes for Black women impacted by triple-negative breast cancer (TNBC). Addressing these barriers is critical to advancing health equity.
Gilead awarded $5.7M in grants to 21 U.S. organizations for programs working to advance health equity for Black people impacted by TNBC.
Two grants are focused on organizational capacity building for Black-led organizations to help enhance their reach and sustainability.
Programmatic grants are focused on supporting local, regional and national approaches to bridging gaps across the cancer care continuum by:
- Addressing the role of social determinants of health in access across the care continuum
- Creating sustainable solutions to promoting racial equity in breast cancer care
- Improving community, patient and provider communication, and relationships and engagement throughout the care continuum
- Providing outreach and education about TNBC for communities, patients, families and caregivers
- Supplying resources to help people navigate the TNBC healthcare journey
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
